Cipla Ltd. is targeting $1 billion in revenue from its US business, with management banking on new launches, regulatory approvals and expansion in specialty products to achieve the milestone.
The company’s shares were trading at Rs 1,385, up 0.28 percent from the previous close. Cipla has a market capitalization of Rs 1,11,915 crore, while the stock has delivered a return of 44 percent over the last five years.
Management remains confident on US growth
Achin Gupta, CEO of Cipla, said the company remains optimistic about growth in the US market.
Management expects rising market penetration, portfolio expansion and execution capabilities to support the company’s ambition of reaching $1 billion in US sales, which implies nearly 30 percent growth from current levels.
Advair approval could provide a boost
One of the key near-term triggers is the expected approval of Cipla’s generic version of Advair.
Management expects approval from the US Food and Drug Administration (US FDA) during the upcoming quarter.
The launch is expected to strengthen Cipla’s respiratory portfolio and support revenue growth in the US generics business.
Pipeline to support long-term growth
Cipla said a strong product pipeline and upcoming regulatory approvals will be crucial in achieving the revenue target.
Management believes regular product launches will provide sustained growth and reduce dependence on a few blockbuster products.
Over the next three years, the company plans to file:
- 40 to 50 products
- Including 12 first-to-file opportunities
These filings are expected to support future approvals and increase market penetration.
Specialty products offer additional opportunity
Management also highlighted the opportunity in Lanreotide, where it expects competition to remain limited.
Lower competition could support pricing stability and help the company gain market share.
Cipla is also exploring alternative manufacturing arrangements in the US to improve supply security and support future demand.
How far is Cipla from the target?
Cipla’s North America business generated $780 million in FY26.
That leaves a gap of around $220 million to achieve the company’s $1 billion goal.
Management believes the existing revenue base, combined with established positions in key therapeutic segments, provides a strong foundation for future growth.
Four respiratory launches planned in FY27
The company expects to commercialise four respiratory products during FY27.
These include:
- Generic Ventolin
- Potential launch of generic Advair
- Two other respiratory products
Management expects these launches to become important growth drivers for the US business.
Focus shifting towards complex products
Cipla is also expanding into higher-value segments.
These include:
- Peptides
- Complex generics
- Biosimilars
The strategy is aimed at diversifying revenue streams and strengthening long-term growth prospects.
Q4 FY26 performance
The company reported lower revenue and profit during the March quarter.
Key numbers for Q4 FY26:
- Revenue from operations fell 3 percent to Rs 6,541 crore, from Rs 6,730 crore in Q4 FY25.
- EBITDA declined 38 percent to Rs 955 crore, compared with Rs 1,538 crore a year earlier.
- Net profit dropped 55 percent to Rs 543 crore, from Rs 1,214 crore.
- Earnings per share (EPS) fell 55 percent to Rs 6.87, against Rs 15.13 in Q4 FY25.
About the company
Founded in 1935, Cipla is headquartered in Mumbai and operates in more than 80 markets worldwide.
The company manufactures generic medicines, respiratory therapies and active pharmaceutical ingredients (APIs). It is the third-largest drug producer in India.
TL;DR:
Cipla is aiming to generate $1 billion in US revenue. Management expects product launches, the anticipated approval of generic Advair and a strong pipeline to drive growth, while expansion into complex products and biosimilars could provide additional support.
AI Summary:
- Cipla is targeting $1 billion in US revenue.
- North America business generated $780 million in FY26.
- Generic Advair approval is expected in the coming quarter.
- The company plans to file 40-50 products over three years.
- Q4 FY26 revenue and profit declined year-on-year.
